Andere talen Cantargia AB

Aandelen

CANTA

SE0006371126

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:47 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,7 ^SEK	-0,80%		-3,14%	-1,02%

17/04	Cantargia publiceert nieuwe gegevens over het Can10-antilichaam, met details over de interactie met IL1RAP en functionele remming	CI
10/04	Cantargia AB (publ) publiceert preklinische gegevens over het potentieel van CAN10 bij systemische sclerose in een toonaangevend wetenschappelijk tijdschrift	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cantargia publishes Annual Report for 2023	18/04
Notice of annual general meeting in Cantargia AB (publ)	18/04
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition	17/04
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	17/04
Cantargia : Proposal regarding share-based incentive scheme	15/04
Cantargia : Proposal regarding guidelines for executive remuneration	15/04
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	10/04
Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal	10/04
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	08/04
Cantargia presents unique effects of nadunolimab in pancreatic cancer	08/04
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	02/04
Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis	02/04
Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia	27/03
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	27/03
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	14/03
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis	14/03
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	05/03
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer	05/03
Cantargia Q4 2023 - Progress with CAN10 and in PDA	23/02
Cantargia publishes Year-End Report for 2023	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cantargia AB

Aandelen

CANTA

SE0006371126

Andere talen

Filters